Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

LY-3971297 is under clinical development by Eli Lilly and Co ... Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US. For a complete picture of LY-3971297’s drug-specific ...

Below, I'm going to dive into what caused Lilly's stock to drop earlier this week and assess if the current price action is a good opportunity to buy the dip. What caused Eli Lilly's stock to fall ...

On Friday, Guggenheim analysts revised their price target for Eli Lilly (NYSE:LLY) shares, reducing it to $973.00 from the previous $995.00, while reiterating a Buy rating on the stock.

Based on its longer-term valuation metrics, I'd argue that Eli Lilly may not be that expensive. Is now a good time to buy Eli Lilly stock? Eli Lilly still looks poised to hit the $1 trillion ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Eli Lilly shares could remain under the microscope on Wednesday after falling sharply ...

Jan 15 (Reuters) - Eli Lilly (LLY.N), opens new tab said on ... The U.S. drugmaker struck a $3.2 billion deal last year to buy Morphic Holding in order to gain access to its experimental oral ...